A randomized, double-blind, placebo- controlled study of LMN-201 for prevention of C. difficile infection recurrence (RePreve)

Status: Recruiting

Eligibility Criteria

Sex: Male or Female
Age Group: 18 years and over
This study is NOT accepting healthy volunteers

Inclusion Criteria:

- diagnosis of Clostridioides Difficile Infection (CDI) defined as a new or recent history of 3 or more bowel movements per day with a loose or watery consistency and a positive stool C. difficile toxin B immunoassay and no other likely explanation for diarrhea - able to take oral medication and willing to adhere to the study medication - have access to a mobile smartphone - women and men of reproductive potential must use of highly effective contraception during study participation and for an additional 4 weeks after the end of study drug administration - see link to clinicaltrials.gov for complete inclusion & exclusion criteria

Exclusion Criteria:

- violent diarrhea from C. difficile colitis - Underlying gastrointestinal disorder characterized by diarrhea such as chronic ulcerative colitis, Crohn's disease, celiac sprue, short bowel syndrome, dumping syndrome following gastrectomy, pancreatic insufficiency, etc. - women who are pregnant, trying to get pregnant or breast feeding

Conditions & Interventions

Conditions:
Infectious Diseases
Keywords:
C-Diff, CDI, Clostridioides Difficile Infection

More Information

Description: This study is recruiting people who have developed an infection of the lower intestine (the colon) by bacteria called Clostridioides difficile (abbreviated C. difficile or C. diff). The standard treatment for this infection is with antibiotics, but in some people, the infection keeps coming back. The purpose of this research is to test whether an investigational drug can prevent a return of the infection. We want to make sure LMN-201 is safe when used as part of standard of care for C. diff, and we want to see if we can improve treatment and reduce re-infection.
Study Contact: Natalie Eichten - eicht024@umn.edu
Principal Investigator: Jo-Anne Young, MD
Phase: PHASE2
IRB Number: STUDY00022202